Kindred Biosciences, Inc.
Kindred Biosciences, Inc. (KIN): 5 pipeline candidates · ~84 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
84.3 months
D/E 0.36
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for Kindred Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$46.7M
Quarterly Burn
$2.6M
Runway
84.3 mo
Revenue
$3.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Frequently asked questions
How many drug candidates are in Kindred Biosciences, Inc.'s pipeline?
Kindred Biosciences, Inc. (KIN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kindred Biosciences, Inc.'s lead drug candidate?
Kindred Biosciences, Inc.'s most advanced tracked candidate is kind-016 (Phase 3) for Atopic dermatitis in dogs.
What is Kindred Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kindred Biosciences, Inc. has approximately 84.3 months of cash runway.
Who is the CEO of Kindred Biosciences, Inc.?
Richard Chin, M.D. is the chief executive officer of Kindred Biosciences, Inc. (KIN).
Get the full picture on Kindred Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.